Skip to main content
. 2017 Dec 14;103(3):497–505. doi: 10.3324/haematol.2017.176164

Figure 3.

Figure 3.

In vivo relationship between BCR signaling and internalization in CLL cells. BCR expression and uptake index were investigated firstly in subsets of peripheral blood (PB) cells (CXCR4brightCD5dim and CXCR4dimCD5bright expressing CLL cells (A-B), and secondly in CD19+CD5+ cells from the matched lymph node (LN) and PB samples from seven unmutated CLL patients (C-D). Thirdly, sIgM expression was measured in CD19+CD5+ PB cells from CLL patients before, one month and at least 12 months after commencing BTKi treatment (ibrutinib, n=6 or acalabrutinib, n=1; presented as a percentage change in surface (s)IgM expression (E-F). Uptake index (G) and the capacity to induce pERK activation following BCR stimulation (H: pERK levels normalized to PMA/positive control) was also examined and compared in CLL B cells, pre- and during treatment. Statistical analysis was performed via Wilcoxon matched pairs test. MFI: mean fluorescent intensity; MESF: molecules of equivalent soluble fluorochrome.